Changes in ctDNA can predict long-term outcomes in certain patients with metastatic CRC on immune checkpoint inhibitors.

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

Jennifer Frederick didn't understand why she had a growing lump under her skin. A doctor returned a devastating diagnosis.

Akeso initiates patient enrolling in phase III trial of ivonescimab for first-line treatment of advanced metastatic colorectal cancer: Hong Kong Thursday, July 17, 2025, 13:00 Hrs ...

Pierre Fabre Laboratories have received marketing authorisation in China for BRAFTOVI (encorafenib) in combination with ...

Cardiff Oncology's onvansertib shows a 64% response rate in early colorectal cancer trials. Click here to read an analysis of ...

Genomill Health, a biotechnology company pioneering simplified targeted library preparation for next-generation sequencing ...

Clinical study in Scientific Reports shows Bridge CaptureTM detects key mutations from blood samples in metastatic colorectal cancer patients ...

Genomill Health’s Bridge Capture technology detects key mutations from blood samples in metastatic colorectal cancer patients: Turku, Finland Wednesday, July 16, 2025, 18:00 Hrs ...

Liquid biopsies have transformed cancer testing. These tests detect signs of cancer using a simple blood draw instead of ...

Cuproptosis represents a novel mechanism of cell death characterized by intracellular copper ion accumulation.